Keywords: correction, tibotec, prezista, february, on-line, article, mistakenly
Correction: Tibotec's Prezista
Article | 26 February 2007
On February 19, in an on-line article, we mistakenly wrote that Fuzeon (enfuvirtide) plus Tibotec's ritonavir-boosted Prezista (darunavir) had been approved ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
